Skip to main content

Table 1 Demographics and Baseline Characteristics of Study Subjects

From: A phase 1 randomized, double-blind, placebo-controlled, crossover trial of DAS181 (Fludase®) in adult subjects with well-controlled asthma

Characteristic Evaluable subjects
N = 10
Age (years)  
 Median (IQR) 22.5 (22, 40)
Sex  
 Female 7 (70 %)
 Male 3 (30 %)
Race  
 White 5 (50 %)
 Black or African American 3 (30 %)
 Asian 1 (10 %)
 Multi-Racial 1 (10 %)
Body Mass Index (kg/m2)  
 Median (IQR) 23.0 (21.4, 24.3)
FEV1, Baseline (day 0)  
Median (IQR) 3.09 (2.78, 3.62)
FEV1 % Predicted, Baseline (day 0)  
Mean (SD) 95.1 (11.6)
PC20, Baseline (screening, mg/m2)  
 Median (IQR) 1.79 (0.49, 3.62)
Asthma Medications (baseline)  
 Short Acting Beta Agonist, inhaled 9 (90 %)
 Long Acting Beta Agonist/Glucocorticoid, inhaled 2 (20 %)
 Glucocorticoid, inhaled 1 (10 %)
 Leukotriene-receptor antagonist 2 (20 %)
  1. Abbreviations: IQR interquartile range, FEV1 forced expiratory volume in 1 second, SD standard deviation, PC 20 provocative concentration producing a 20 % decline (PC20)